Morning Market Losers

tumbled 46.63 percent to $1.98 following news from the company's licensing partner UCB that Phase III trial for Epratuzumab in Lupus did not hit statistically significant results.

shares slipped 14.12 percent to $169.77 after the company reported Q2 results and issued a weak sales forecast for the third quarter.

shares declined 12.62 percent to $34.61 on weaker-than-expected FQ1 results.

fell 12.26 percent to $17.60 after the company reported downbeat Q2 results.

shares dipped 10.47 percent to $4.41 after the company reported downbeat Q2 results and issued a weak Q3 outlook.

declined 7.62 percent to $1.09. Smith Micro Software reported a Q2 adjusted loss of $0.01 per share on sales of $9.39 million.

dropped 7.14 percent to $24.18 on downbeat Q2 earnings.

shares declined 3.12 percent to $2.70. AudioCodes reported a Q2 loss of $(0.01) per share on revenue of $32.405 million.